Osteoporosis

FDA approves Actonel for once-a-week use

Published in Women's Health Weekly, July 4th, 2002

The U.S. Food and Drug Administration (FDA) has approved a new 35 mg once-a-week dosage strength for Actonel (risedronate sodium tablets) for the prevention and treatment of postmenopausal osteoporosis. It will be available in mid-June 2002, by prescription only.

Robert Lindsay, MD, PhD, chief of internal medicine at Helen Hayes Hospital, Professor of Clinical Medicine, Columbia University, and principal investigator of the Actonel once-a-week approval study, stated that patients and doctors always welcome effective new treatment choices, and now there is data showing that once-a-week dosing of Actonel is therapeutically equivalent to daily 5 mg dosing.

...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Weekly

Source: Women's Health Weekly (2002-07-04)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry